ANNAPOLIS, Md., May 4 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medicalcountermeasures against biological and chemical threats, today announced that the Company's Interim CEO, Eric I. Richman, will be participating on a special biosecurity panel presentation promoting the critical interrelationship
The panel presentation, entitled "Public Private Partnerships for State-of-the-Art Countermeasures" will be held at 4:00 pm EDT on Wednesday, May 5, 2010, as part of the inaugural 2010 Biosecurity Conference, co-located with the 2010 BIO International Conference, May 3-6, 2010, McCormick Place, Chicago, IL.
Officials in the biodefense industry note that increasing our nation's capability to rapidly and effectively develop and produce new and better medical countermeasures might not simply prevent casualties, but reduce the likelihood of such an attack. Panelists, which include senior government officials and leading industry representatives will assess the process for the creation of these countermeasures and analyze the successes and challenges in their development through case studies and discussion, with the goal of enhancing our biodefense readiness and strategic national arsenal.
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:
For more information about PharmAthene, please visit www.PharmAthene.com.
SOURCE PharmAthene, Inc.
Subscribe to our Free Newsletters!
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...
Video-electroencephalography monitoring is a diagnostic technique that records the electrical ...
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...View All